BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

...acquired glibenclamide IV, an antagonist of ATP-binding cassette sub-family C member 8 (ABCC8; SUR1), from Remedy Pharmaceuticals Inc....
BioCentury | Feb 9, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

...acquired IV glibenclamide (BIIB093), an ATP-binding cassette sub-family C member 8 (ABCC8; SUR1) antagonist, from Remedy Pharmaceuticals Inc....
BioCentury | Feb 7, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

...acquired IV glibenclamide (BIIB093), an ATP-binding cassette sub-family C member 8 (ABCC8; SUR1) antagonist, from Remedy Pharmaceuticals Inc....
BioCentury | Jul 25, 2017
Company News

Spinraza sales drive Biogen's guidance bump

...a mAb targeting microtubule-associated protein tau (tau; MAPT; FTDP-17), and $120 million up front to Remedy Pharmaceuticals Inc....
BioCentury | May 19, 2017
Company News

Biogen adds to stroke portfolio with Cirara acquisition

...Biogen Inc. (NASDAQ:BIIB) acquired acute ischemic stroke candidate Cirara glyburide (RP-1127) from Remedy Pharmaceuticals Inc. (New York, N.Y...
...SUR1). Remedy Pharmaceuticals Inc. , New York, N.Y. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Neurology Jaime De Leon Cirara glyburide RP-1127 Biogen Inc. Remedy Pharmaceuticals Inc. ATP-binding...
BioCentury | May 15, 2017
Company News

Biogen adds to stroke portfolio with Cirara acquisition

...Biogen Inc. (NASDAQ:BIIB) acquired acute ischemic stroke candidate Cirara glyburide (RP-1127) from Remedy Pharmaceuticals Inc. (New York, N.Y...
...sub-family C member 8 (ABCC8; SUR1). Biogen gained $3.69 to $258.53 on Monday. Jaime De Leon AN100226 Cirara glyburide natalizumab RP-1127 Tysabri Biogen Inc. Remedy Pharmaceuticals Inc. ATP-binding...
BioCentury | Feb 29, 2016
Clinical News

Cirara glyburide: Additional Phase II data

...need for decompressive craniotomy vs. placebo (42% vs. 39%, p=0.77) (see BioCentury, Oct. 26, 2015). Remedy Pharmaceuticals Inc....
BioCentury | Dec 7, 2015
Financial News

Remedy Pharmaceuticals completes venture financing

Remedy Pharmaceuticals Inc. , New York, N.Y. Business: Neurology Date completed: 2015-12-01 Type: Venture financing Raised: $9 million Investors: Vertical Group; existing investors; new investors WIR Staff Neurology...
BioCentury | Oct 26, 2015
Clinical News

Glyburide: Preliminary Phase II data

...Scottsdale. Remedy said it will meet with FDA to discuss Phase III plans for Cirara. Remedy Pharmaceuticals Inc....
BioCentury | Sep 21, 2015
Clinical News

Glyburide: Phase IIa started

...continuous infusion of 0.16 mg/hour for 6 hours and then 0.11 mg/hour for 66 hours. Remedy Pharmaceuticals Inc....
Items per page:
1 - 10 of 15
BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

...acquired glibenclamide IV, an antagonist of ATP-binding cassette sub-family C member 8 (ABCC8; SUR1), from Remedy Pharmaceuticals Inc....
BioCentury | Feb 9, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

...acquired IV glibenclamide (BIIB093), an ATP-binding cassette sub-family C member 8 (ABCC8; SUR1) antagonist, from Remedy Pharmaceuticals Inc....
BioCentury | Feb 7, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

...acquired IV glibenclamide (BIIB093), an ATP-binding cassette sub-family C member 8 (ABCC8; SUR1) antagonist, from Remedy Pharmaceuticals Inc....
BioCentury | Jul 25, 2017
Company News

Spinraza sales drive Biogen's guidance bump

...a mAb targeting microtubule-associated protein tau (tau; MAPT; FTDP-17), and $120 million up front to Remedy Pharmaceuticals Inc....
BioCentury | May 19, 2017
Company News

Biogen adds to stroke portfolio with Cirara acquisition

...Biogen Inc. (NASDAQ:BIIB) acquired acute ischemic stroke candidate Cirara glyburide (RP-1127) from Remedy Pharmaceuticals Inc. (New York, N.Y...
...SUR1). Remedy Pharmaceuticals Inc. , New York, N.Y. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Neurology Jaime De Leon Cirara glyburide RP-1127 Biogen Inc. Remedy Pharmaceuticals Inc. ATP-binding...
BioCentury | May 15, 2017
Company News

Biogen adds to stroke portfolio with Cirara acquisition

...Biogen Inc. (NASDAQ:BIIB) acquired acute ischemic stroke candidate Cirara glyburide (RP-1127) from Remedy Pharmaceuticals Inc. (New York, N.Y...
...sub-family C member 8 (ABCC8; SUR1). Biogen gained $3.69 to $258.53 on Monday. Jaime De Leon AN100226 Cirara glyburide natalizumab RP-1127 Tysabri Biogen Inc. Remedy Pharmaceuticals Inc. ATP-binding...
BioCentury | Feb 29, 2016
Clinical News

Cirara glyburide: Additional Phase II data

...need for decompressive craniotomy vs. placebo (42% vs. 39%, p=0.77) (see BioCentury, Oct. 26, 2015). Remedy Pharmaceuticals Inc....
BioCentury | Dec 7, 2015
Financial News

Remedy Pharmaceuticals completes venture financing

Remedy Pharmaceuticals Inc. , New York, N.Y. Business: Neurology Date completed: 2015-12-01 Type: Venture financing Raised: $9 million Investors: Vertical Group; existing investors; new investors WIR Staff Neurology...
BioCentury | Oct 26, 2015
Clinical News

Glyburide: Preliminary Phase II data

...Scottsdale. Remedy said it will meet with FDA to discuss Phase III plans for Cirara. Remedy Pharmaceuticals Inc....
BioCentury | Sep 21, 2015
Clinical News

Glyburide: Phase IIa started

...continuous infusion of 0.16 mg/hour for 6 hours and then 0.11 mg/hour for 66 hours. Remedy Pharmaceuticals Inc....
Items per page:
1 - 10 of 15